Commentary

Video

Tissue vs Liquid Biopsies for Biomarker Testing in NSCLC

Author(s):

Jessica Donington, MD, MSCR,Melina Elpi Marmarelis, MD

Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on tissue and liquid biopsies for biomarker testing in NSCLC.

Related Videos
Alec Watson, MD
Balazs Halmos, MD
Balazs Halmos, MD
Eunice S. Wang, MD
Marcella Ali Kaddoura, MD
Suresh Senan, MRCP, FRCR, PhD, full professor, treatment and quality of life, full professor, cancer biology and immunology, full professor, radiation oncology, professor, clinical experimental radiotherapy, Amsterdam University Medical Centers
Alison Schram, MD
Mary B. Beasley, MD, discusses molecular testing challenges in non–small cell lung cancer and pancreatic cancer.
Mary B. Beasley, MD, discusses the multidisciplinary management of NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Mary B. Beasley, MD, discusses the role of pathologists in molecular testing in non–small cell lung cancer and pancreatic cancer.
Related Content
OncLive's OncFive: The Top 5 Oncology Articles of the Week
December 21st 2024

The OncFive: Top Oncology Articles for the Week of 12/15

MedNews Week
December 12th 2024

Delve Into Data With Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC: With Chandler Park, MD; and Stephen Liu, MD

FDA
December 20th 2024

FDA Grants Accelerated Approval to Encorafenib Plus Cetuximab and Chemo for BRAF V600E+ Metastatic Colorectal Cancer

Ongoing Research Advances Equity and Precision Oncology Through Tissue-Agnostic Therapies: With Chandler Park, MD, and Vivek Subbiah, MD
October 30th 2024

Ongoing Research Advances Equity and Precision Oncology Through Tissue-Agnostic Therapies: With Chandler Park, MD, and Vivek Subbiah, MD

Zongertinib Elicits Durable Responses in Pretreated Advanced HER2-Mutant NSCLC
December 20th 2024

Zongertinib Elicits Durable Responses in Pretreated Advanced HER2-Mutant NSCLC

FDA
December 18th 2024

FDA Approves Ensartinib for Locally Advanced or Metastatic ALK+ NSCLC